Turoctocog alfa

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Haemophilia A

Conditions

Haemophilia A

Trial Timeline

Jun 12, 2018 → Jun 19, 2019

NCT ID

NCT03588741

About Turoctocog alfa

Turoctocog alfa is a phase 3 stage product being developed by Novo Nordisk for Haemophilia A. The current trial status is terminated. This product is registered under clinical trial identifier NCT03588741. Target conditions include Haemophilia A.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06574984	Pre-clinical	Recruiting	Nov 10, 2024	Apr 30, 2026	Congenital Bleeding Disorder
NCT04584892	Pre-clinical	Completed	Apr 12, 2021	Mar 27, 2023	Haemophilia A
NCT03179748	Pre-clinical	Completed	Jun 20, 2018	Jun 16, 2021	Congenital Bleeding Disorder
NCT03588741	Phase 3	Terminated	Jun 12, 2018	Jun 19, 2019	Haemophilia A
NCT03449342	Approved	Completed	Mar 1, 2018	Apr 22, 2019	Congenital Bleeding Disorder
NCT02941354	Phase 1	Completed	Oct 10, 2016	Jun 20, 2017	Congenital Bleeding Disorder
NCT02207218	Pre-clinical	Completed	Aug 4, 2014	Nov 10, 2020	Congenital Bleeding Disorder
NCT02035384	Pre-clinical	Completed	Jun 5, 2014	Jan 15, 2020	Congenital Bleeding Disorder
NCT01493778	Phase 3	Completed	Sep 17, 2012	Dec 5, 2018	Congenital Bleeding Disorder
NCT01365520	Phase 1	Completed	Jun 1, 2011	Sep 1, 2011	Congenital Bleeding Disorder
NCT01238367	Phase 1	Completed	Nov 1, 2010	Oct 1, 2011	Congenital Bleeding Disorder
NCT00840086	Phase 3	Completed	Apr 1, 2009	Sep 1, 2011	Congenital Bleeding Disorder

Competing Products

20 competing products in Haemophilia A

See all competitors

Product	Company	Stage	Hype Score
Mim8	Novo Nordisk	Phase 3	76
NNC0365-3769 (Mim8)	Novo Nordisk	Phase 3	76
Turoctocog alfa pegol	Novo Nordisk	Pre-clinical	22
Mim8 B, 10 mg/mL + Mim8 B, 100 mg/mL + Mim8 B, placebo	Novo Nordisk	Phase 1	32
Turoctocog alfa pegol	Novo Nordisk	Pre-clinical	22
Concizumab	Novo Nordisk	Phase 3	76
Concizumab	Novo Nordisk	Phase 3	76
turoctocog alfa pegol (N8-GP)	Novo Nordisk	Phase 3	76
Concizumab	Novo Nordisk	Phase 3	76
Esperoct	Novo Nordisk	Pre-clinical	22
NNC0442-0344 A	Novo Nordisk	Phase 1	32
NNC0365-3769 (Mim8) PPX	Novo Nordisk	Phase 3	76
Concizumab	Novo Nordisk	Pre-clinical	22
Refixia®	Novo Nordisk	Pre-clinical	22
NNC0442-0344 A + Placebo	Novo Nordisk	Phase 1	32
Mim8	Novo Nordisk	Phase 3	76
Turoctocog alfa pegol (N8-GP)	Novo Nordisk	Pre-clinical	22
Nonacog beta pegol	Novo Nordisk	Pre-clinical	22
Concizumab	Novo Nordisk	Pre-clinical	22
Turoctocog alfa	Novo Nordisk	Pre-clinical	22

Other Products from Novo Nordisk

Liraglutide 3.0mg + Placebo Oral Tablet + Phentermine 15 MGApproved

Liraglutide + SalineApproved

Hydrocortisone + PlaceboApproved

biphasic insulin aspart + insulin aspartApproved

Semaglutide, 1.34 mg/mL + Empagliflozin 25 MGApproved